Matches in SemOpenAlex for { <https://semopenalex.org/work/W588016281> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W588016281 endingPage "1034" @default.
- W588016281 startingPage "1034" @default.
- W588016281 abstract "1034 Background: Anthracycline-taxane combinations are among the most active chemotherapy regimens for BC. We conducted a phase III trial to explore whether adding X to ET could further improve outcomes. Methods: Patients (pts) with stage IIIb or IV BC were randomized to 3-weekly cycles of either ET (E 75 mg/m2 + T 75 mg/m2, both d1) or TEX (ET as above + X 1000 mg/m2 bid, d1–14). Primary endpoint was progression-free survival (PFS). We report results in the 271 stage IV pts; data from the 71 stage III pts will be presented when mature. Results: Baseline characteristics were well balanced. In the TEX and ET arms, respectively, 49% vs 50% had received prior chemotherapy (anthracycline in 29% of both arms); 59% vs 65% had visceral metastases; median disease-free interval was 25.0 vs 29.5 months. Median follow-up in the total population (stage IIIb and IV) at data cut-off was 27.2 and 28.4 months, respectively. With TEX, median delivered dose of X was 87% of the planned dose. 100% of planned E and T was delivered in both arms. TEX was well tolerated. In the overall population (stage IIIb and IV), there was no grade 4 diarrhea; grade 3 diarrhea and hand-foot syndrome occurred in 8% and 3% of TEX pts, respectively. Conclusions: A triple combination of three of the most active agents for BC is highly active. RR was significantly superior with TEX vs ET. Although not statistically significant, a benefit in PFS and OS (absolute difference 6.7 months) was observed with the addition of X to ET. TEX (n=136) ET (n=135) P value Response rate (RR) 67% 53% 0.02 CR 16% 5% - PR 51% 47% - PFS Events 110 (81%) 111 (82%) - Median, months (95% CI) 12.3 (11.1–15.1) 9.8 (8.4–12.9) 0.26 Overall survival (OS) Events, n (%) 71 (52%) 80 (59%) - Median, months (95% CI) 34.5 (28.2–46.5) 27.8 (22.4–42.9) 0.19 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Eli Lilly, Hoffmann-La Roche" @default.
- W588016281 created "2016-06-24" @default.
- W588016281 creator A5009976972 @default.
- W588016281 creator A5027273924 @default.
- W588016281 creator A5037733792 @default.
- W588016281 creator A5038784620 @default.
- W588016281 creator A5041125823 @default.
- W588016281 creator A5074479074 @default.
- W588016281 creator A5076325009 @default.
- W588016281 creator A5090055323 @default.
- W588016281 date "2008-05-20" @default.
- W588016281 modified "2023-09-26" @default.
- W588016281 title "Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC)" @default.
- W588016281 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.1034" @default.
- W588016281 hasPublicationYear "2008" @default.
- W588016281 type Work @default.
- W588016281 sameAs 588016281 @default.
- W588016281 citedByCount "3" @default.
- W588016281 countsByYear W5880162812012 @default.
- W588016281 crossrefType "journal-article" @default.
- W588016281 hasAuthorship W588016281A5009976972 @default.
- W588016281 hasAuthorship W588016281A5027273924 @default.
- W588016281 hasAuthorship W588016281A5037733792 @default.
- W588016281 hasAuthorship W588016281A5038784620 @default.
- W588016281 hasAuthorship W588016281A5041125823 @default.
- W588016281 hasAuthorship W588016281A5074479074 @default.
- W588016281 hasAuthorship W588016281A5076325009 @default.
- W588016281 hasAuthorship W588016281A5090055323 @default.
- W588016281 hasConcept C121608353 @default.
- W588016281 hasConcept C126322002 @default.
- W588016281 hasConcept C141071460 @default.
- W588016281 hasConcept C146357865 @default.
- W588016281 hasConcept C151730666 @default.
- W588016281 hasConcept C168563851 @default.
- W588016281 hasConcept C203092338 @default.
- W588016281 hasConcept C2776694085 @default.
- W588016281 hasConcept C2776802502 @default.
- W588016281 hasConcept C2777511904 @default.
- W588016281 hasConcept C2777909004 @default.
- W588016281 hasConcept C2780739268 @default.
- W588016281 hasConcept C2780835546 @default.
- W588016281 hasConcept C2781190966 @default.
- W588016281 hasConcept C2908647359 @default.
- W588016281 hasConcept C31760486 @default.
- W588016281 hasConcept C526805850 @default.
- W588016281 hasConcept C530470458 @default.
- W588016281 hasConcept C71924100 @default.
- W588016281 hasConcept C86803240 @default.
- W588016281 hasConcept C90924648 @default.
- W588016281 hasConcept C99454951 @default.
- W588016281 hasConceptScore W588016281C121608353 @default.
- W588016281 hasConceptScore W588016281C126322002 @default.
- W588016281 hasConceptScore W588016281C141071460 @default.
- W588016281 hasConceptScore W588016281C146357865 @default.
- W588016281 hasConceptScore W588016281C151730666 @default.
- W588016281 hasConceptScore W588016281C168563851 @default.
- W588016281 hasConceptScore W588016281C203092338 @default.
- W588016281 hasConceptScore W588016281C2776694085 @default.
- W588016281 hasConceptScore W588016281C2776802502 @default.
- W588016281 hasConceptScore W588016281C2777511904 @default.
- W588016281 hasConceptScore W588016281C2777909004 @default.
- W588016281 hasConceptScore W588016281C2780739268 @default.
- W588016281 hasConceptScore W588016281C2780835546 @default.
- W588016281 hasConceptScore W588016281C2781190966 @default.
- W588016281 hasConceptScore W588016281C2908647359 @default.
- W588016281 hasConceptScore W588016281C31760486 @default.
- W588016281 hasConceptScore W588016281C526805850 @default.
- W588016281 hasConceptScore W588016281C530470458 @default.
- W588016281 hasConceptScore W588016281C71924100 @default.
- W588016281 hasConceptScore W588016281C86803240 @default.
- W588016281 hasConceptScore W588016281C90924648 @default.
- W588016281 hasConceptScore W588016281C99454951 @default.
- W588016281 hasIssue "15_suppl" @default.
- W588016281 hasLocation W5880162811 @default.
- W588016281 hasOpenAccess W588016281 @default.
- W588016281 hasPrimaryLocation W5880162811 @default.
- W588016281 hasRelatedWork W1942209073 @default.
- W588016281 hasRelatedWork W1999778859 @default.
- W588016281 hasRelatedWork W2023605960 @default.
- W588016281 hasRelatedWork W2041321380 @default.
- W588016281 hasRelatedWork W2061287119 @default.
- W588016281 hasRelatedWork W2088293437 @default.
- W588016281 hasRelatedWork W2331609118 @default.
- W588016281 hasRelatedWork W3028773022 @default.
- W588016281 hasRelatedWork W3081058368 @default.
- W588016281 hasRelatedWork W588016281 @default.
- W588016281 hasVolume "26" @default.
- W588016281 isParatext "false" @default.
- W588016281 isRetracted "false" @default.
- W588016281 magId "588016281" @default.
- W588016281 workType "article" @default.